Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

The primary objective of the study is to evaluate the effect on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight \> 75 Kg/m2 being administered with a 3 g/day polyglucosamine dosage. The secondary objectives of the study are: * to evaluate the effect of supplementation on blood triglyceride levels * to evaluate the effect of supplementation on blood levels of Total Cholesterol (CT), LDL, and HDL * to evaluate the effect of supplementation on glucose, insulin, insulin resistance assessed by calculating the Homeostatic metabolic assessment (HOMA) * to evaluate the effect of supplementation on liver enzymes (transaminases) and renal function (creatinine) * to evaluate the effect of supplementation on BMI (Body Mass Index) * to evaluate the effect of supplementation on the abdominal circumference * to evaluate the effect of supplementation on body composition evaluated by dual X-ray densitometer (DXA) * to evaluate the effect of supplementation on the serum levels of reactive oxygen species * to evaluate the effect of supplementation on serum antioxidant capacity